LigaChem Biosciences Inc. (KOSDAQ:141080) On The Verge Of Breaking Even

With the business potentially at an important milestone, we thought we'd take a closer look at LigaChem Biosciences Inc.'s (KOSDAQ:141080) future prospects. LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. With the latest financial year loss of ₩74b and a trailing-twelve-month loss of ₩2.9b, the ₩4.4t market-cap company alleviated its loss by moving closer towards its target of breakeven. The most pressing concern for investors is LigaChem Biosciences' path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

Check out our latest analysis for LigaChem Biosciences

LigaChem Biosciences is bordering on breakeven, according to the 5 South Korean Life Sciences analysts. They expect the company to post a final loss in 2024, before turning a profit of ₩60b in 2025. The company is therefore projected to breakeven around a year from now or less! How fast will the company have to grow to reach the consensus forecasts that anticipate breakeven by 2025? Working backwards from analyst estimates, it turns out that they expect the company to grow 99% year-on-year, on average, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Underlying developments driving LigaChem Biosciences' growth isn’t the focus of this broad overview, however, keep in mind that generally a life science company has lumpy cash flows which are contingent on the product and stage of development the company is in. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital judiciously, with debt making up 1.9% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are too many aspects of LigaChem Biosciences to cover in one brief article, but the key fundamentals for the company can all be found in one place – LigaChem Biosciences' company page on Simply Wall St. We've also compiled a list of pertinent factors you should further examine:

1. Valuation: What is LigaChem Biosciences worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether LigaChem Biosciences is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on LigaChem Biosciences’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.